Ward S, Weatherley B C
Br J Anaesth. 1986;58 Suppl 1:6S-10S. doi: 10.1093/bja/58.suppl_1.6s.
The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease. Its short elimination half-life was not significantly altered by renal failure, but in patients with severe liver disease elimination of its metabolites was prolonged, necessitating care during long-term i.v. infusions in patients with hepatic dysfunction.
在正常患者以及肾衰竭、肝肾衰竭或肝病患者中研究了阿曲库铵的药代动力学特征。肾衰竭对其较短的消除半衰期没有显著影响,但在重症肝病患者中,其代谢产物的消除时间延长,因此在肝功能不全患者进行长期静脉输注时需要谨慎。